Corporate Overview

Headquartered in Austin, Texas, Mati Therapeutics is developing a non-invasive sustained drug delivery platform to treat ocular diseases, in particular glaucoma.

The founders of Mati held senior leadership positions at Allergan, AMO, and Abbott Laboratories. In additon, the four founders of Mati previously worked together at QLT Inc., a publicly traded Vancouver-based biotech company focused on ocular diseases and the company responsible for developing Visudyne®, the first medical treatment for age related macular degeneration.